Krystal Biotech Announces Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates
• Net product revenue of $42.1M in 4Q and $50.7M for the year • New England Journal of Medicine publication of […]
BullFrog AI Appoints Globally Renowned Biomedical AI Expert Dr. Thomas W. Chittenden as Chief Scientific Officer
GAITHERSBURG, Md., Feb. 26, 2024 (GLOBE NEWSWIRE) — BullFrog AI Holdings, Inc. (NASDAQ: BFRG; BFRGW) (“BullFrog AI” or the “Company”), […]
Daxor Corporation to Exhibit at the Technology and Heart Failure Therapeutics Conference
Oak Ridge, TN, Feb. 26, 2024 (GLOBE NEWSWIRE) — Daxor Corporation (NASDAQ: DXR), the global leader in blood volume measurement […]
Cognition Therapeutics to Present at the TD Cowen Health Care Conference
PURCHASE, N.Y., Feb. 26, 2024 (GLOBE NEWSWIRE) — Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage company developing product candidates […]
Applied Materials Expands Patterning Solutions Portfolio for Angstrom Era Chipmaking
Applied is working with all leading-edge logic chipmakers on a growing number of applications for its Sculpta®pattern-shaping technology Introducing innovative […]
Surgery Partners, Inc. Announces Fourth Quarter and Full Year 2023 Results; Sets 2024 Guidance
BRENTWOOD, Tenn., Feb. 26, 2024 (GLOBE NEWSWIRE) — Surgery Partners, Inc. (NASDAQ:SGRY) (“Surgery Partners” or the “Company”), a leading short-stay surgical [...]
Wearable Devices to Showcase Its Neural Gesture Control Technology at MWC Barcelona 2024
The Company will demonstrate its Mudra Developer Kit for B2B partners as well as the Mudra Band for Apple Watch […]
Gilat Presents Fourth Quarter and Full Year 2023 Results
Q4 Revenue of $75.6 million, GAAP Operating Income of $2.9 million and Adjusted EBITDA of $9.4 million 2023 Revenue of […]
Allakos Presents Preclinical Data Highlighting Inhibition of MRGPRX2-Mediated Mast Cell Activation with AK006 at AAAAI 2024
– Atopic dermatitis and prurigo nodularis skin lesions show evidence of MRGPRX2 mast cell activation and activated macrophages – – […]
Celldex Reports Fourth Quarter and Year End 2023 Financial Results and Provides Corporate Update
– Phase 3 CSU studies expected to initiate in summer 2024 –– Positive Phase 2 CSU 12 week data reported […]
